Presentation: Paradigm Biopharma - Ignite Investment Summit, Hong Kong, April 2026

Paradigm Biopharma is a clinical-stage drug development company focused on developing innovative therapies for diseases with significant unmet medical need, with an initial focus on osteoarthritis. The company’s lead program is injectable pentosan polysulfate sodium (iPPS), also known as Zilosul®, which is currently being evaluated in a global Phase 3 clinical trial for the treatment of knee osteoarthritis. Paradigm’s strategy centres on identifying and advancing promising pharmaceutical compounds with established safety profiles into new therapeutic indications supported by strong intellectual property and clinical development pathways. In addition to its osteoarthritis program, the company continues to explore the broader therapeutic potential of pentosan polysulfate sodium across other inflammatory and rare disease indications. Speaker: Paul Rennie, Founder & Executive Chairman Stage: Phase III Clinical Development Stock Code: ASX:PAR This was recorded at our Hong Kong Ignite Investment Summit from 15 - 16 April 2026. For more information about Ignite Summits, click here: https://weareignite.com/ ‪@paradigmbiopharmaceuticals9350‬